Sign Out
No well-controlled studies with Timo-COMOD 0.5% in pregnant and breast-feeding women exist. Therefore, the expected benefit has to be balanced precisely against the possible risks.
When Timo-COMOD 0.5% is applied to the mother shortly before delivery, bradycardia, hypoglycemia and respiratory depression in the neonate may occur; there are reports about β-blockage in neonates with other β-blockers. Neonates therefore should be observed carefully for several days after delivery.
Lactation: After ocular administration, timolol is secreted into breast milk and may accumulate to higher concentrations than in the mother's plasma. Although the amount of active ingredient thus received in breast milk is probably of no risk for the newborn, the child should be carefully observed for symptoms of β1-blockade.
Continue with Google